First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, China; Department of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, China.
Department of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, China.
Biomed Pharmacother. 2018 Apr;100:324-334. doi: 10.1016/j.biopha.2018.02.025. Epub 2018 Feb 16.
Tengfu Jiangya tablet (TJT) is a traditional Chinese medicine formulation composed of Uncaria rhynchophylla and Semen raphani. It is a hospital preparation that is widely used in clinics for treating hypertension. A previous metabolomics study reported that TJT exerted a protective effect on hypertension by restoring impaired NO production, ameliorating the inflammatory state, and vascular remodeling. A clinical proteomics study also revealed five key target proteins during TJT intervention. This study aimed to integrate proteome and metabolome data sets for a holistic view of the molecular mechanisms of TJT in treating hypertension.
Serum samples from spontaneously hypertensive rats and Wistar Kyoto rats were analyzed using ultra-high performance liquid chromatography coupled to Q Exactive hybrid quadrupole-Orbitrap mass spectrometry (UPLC-Q-Exactive-MS)-based metabolomics technology and isobaric tags for relative and absolute quantitation (iTRAQ)-based quantitative proteomics technology. Moreover, we selected two candidate proteins and determined their expression levels in rat serum using an enzyme-linked immunosorbent assay (ELISA).
A total of 20 potential biomarkers and 14 differential proteins in rat serum were identified. These substances were mainly involved in three biological pathways: the kallikrein-kinin pathway, the lipid metabolism pathway, and the PPARγ signaling pathway.
The results suggested that TJT could effectively treat hypertension, partially by regulating the above three metabolic pathways. The combination of proteomics and metabolomics provided a feasible method to uncover the underlying interventional effect and therapeutic mechanism of TJT on spontaneously hypertensive rats.
藤附降压片(TJT)是一种由钩藤和莱菔子组成的中药方剂。它是一种广泛应用于临床治疗高血压的医院制剂。先前的代谢组学研究报告称,TJT 通过恢复受损的 NO 产生、改善炎症状态和血管重塑来发挥保护作用。一项临床蛋白质组学研究也揭示了 TJT 干预期间的五个关键靶蛋白。本研究旨在整合蛋白质组和代谢组数据集,以全面了解 TJT 治疗高血压的分子机制。
使用超高效液相色谱- Q Exactive 混合四极杆-Orbitrap 质谱(UPLC-Q-Exactive-MS)-基于代谢组学技术和等重标记相对和绝对定量(iTRAQ)-基于定量蛋白质组学技术分析自发性高血压大鼠和 Wistar Kyoto 大鼠的血清样本。此外,我们选择了两个候选蛋白,并使用酶联免疫吸附测定(ELISA)法测定了它们在大鼠血清中的表达水平。
共鉴定出 20 种潜在的生物标志物和 14 种大鼠血清中的差异蛋白。这些物质主要涉及三个生物学途径:激肽释放酶-激肽途径、脂质代谢途径和 PPARγ 信号通路。
结果表明,TJT 可有效治疗高血压,部分通过调节上述三种代谢途径。蛋白质组学和代谢组学的结合为揭示 TJT 对自发性高血压大鼠的干预作用和治疗机制提供了一种可行的方法。